Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study (Q43263933)
Jump to navigation
Jump to search
scientific article published on 6 October 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study |
scientific article published on 6 October 2009 |
Statements
1 reference
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study (English)
1 reference
Per-Uno Malmström
1 reference
Pekka Hellström
1 reference
Milos Duchek
1 reference
Robert Johansson
1 reference
Staffan Jahnson
1 reference
Oddvar Mestad
1 reference
Sverker Hellsten
1 reference
Members of the Urothelial Cancer Group of the Nordic Association of Urology
1 reference
6 October 2009
1 reference
1 reference
57
1 reference
1
1 reference
25-31
1 reference
Identifiers
1 reference
1 reference